Væksthormonbehandling af korte børn født small for gestational age

Henrik B Thybo Christesen; Rikke Bodin Beck Jensen; Niels H Birkebaek; Niels Thomas Hertel; Katharina M Main; Henrik B Mortensen; Rune W Naeraa; Anders Juul

Væksthormonbehandling af korte børn født small for gestational age

Henrik B Thybo Christesen
, Rikke Bodin Beck Jensen
, Niels H Birkebaek
, Niels Thomas Hertel
, Katharina M Main
, Henrik B Mortensen
, Rune W Naeraa
, Anders Juul

2 Citationer (Scopus)

Abstract

Short children born small for gestational age (SGA) are defined as having a birth weight below -2 SD for gestational age and a reduced height at four years of age (height <-2.5 SD). Growth hormone (GH) treatment significantly improves final height (mean height gain 12 centimetres) in such children. Consequently, GH therapy has been an approved indication in Europe since 2003 for SGA children who remain short at four years of age. The Danish consensus guidelines for diagnosis, treatment and control of short SGA children are described in this review.

Bidragets oversatte titel	Growth hormone treatment of short children born small for gestational age
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	168
Udgave nummer	9
Sider (fra-til)	889-95
Antal sider	7
Status	Udgivet - 2006

Emneord

Body Height
Child, Preschool
Female
Fetal Growth Retardation
Growth Disorders
Growth Hormone
Humans
Infant, Newborn
Infant, Small for Gestational Age
Male
Practice Guidelines as Topic
Randomized Controlled Trials as Topic

Citationsformater

@article{229d73d1a6e141abb852eb072d82567c,

title = "V{\ae}ksthormonbehandling af korte b{\o}rn f{\o}dt small for gestational age",

abstract = "Short children born small for gestational age (SGA) are defined as having a birth weight below -2 SD for gestational age and a reduced height at four years of age (height <-2.5 SD). Growth hormone (GH) treatment significantly improves final height (mean height gain 12 centimetres) in such children. Consequently, GH therapy has been an approved indication in Europe since 2003 for SGA children who remain short at four years of age. The Danish consensus guidelines for diagnosis, treatment and control of short SGA children are described in this review.",

keywords = "Body Height, Child, Preschool, Female, Fetal Growth Retardation, Growth Disorders, Growth Hormone, Humans, Infant, Newborn, Infant, Small for Gestational Age, Male, Practice Guidelines as Topic, Randomized Controlled Trials as Topic",

author = "Christesen, \{Henrik B Thybo\} and Jensen, \{Rikke Bodin Beck\} and Birkebaek, \{Niels H\} and Hertel, \{Niels Thomas\} and Main, \{Katharina M\} and Mortensen, \{Henrik B\} and Naeraa, \{Rune W\} and Anders Juul",

year = "2006",

language = "Dansk",

volume = "168",

pages = "889--95",

journal = "Ugeskrift for Laeger",

issn = "1399-4174",

publisher = "Almindelige Danske L{\ae}geforening",

number = "9",

}

TY - JOUR

T1 - Væksthormonbehandling af korte børn født small for gestational age

AU - Christesen, Henrik B Thybo

AU - Jensen, Rikke Bodin Beck

AU - Birkebaek, Niels H

AU - Hertel, Niels Thomas

AU - Main, Katharina M

AU - Mortensen, Henrik B

AU - Naeraa, Rune W

AU - Juul, Anders

PY - 2006

Y1 - 2006

N2 - Short children born small for gestational age (SGA) are defined as having a birth weight below -2 SD for gestational age and a reduced height at four years of age (height <-2.5 SD). Growth hormone (GH) treatment significantly improves final height (mean height gain 12 centimetres) in such children. Consequently, GH therapy has been an approved indication in Europe since 2003 for SGA children who remain short at four years of age. The Danish consensus guidelines for diagnosis, treatment and control of short SGA children are described in this review.

AB - Short children born small for gestational age (SGA) are defined as having a birth weight below -2 SD for gestational age and a reduced height at four years of age (height <-2.5 SD). Growth hormone (GH) treatment significantly improves final height (mean height gain 12 centimetres) in such children. Consequently, GH therapy has been an approved indication in Europe since 2003 for SGA children who remain short at four years of age. The Danish consensus guidelines for diagnosis, treatment and control of short SGA children are described in this review.

KW - Body Height

KW - Child, Preschool

KW - Female

KW - Fetal Growth Retardation

KW - Growth Disorders

KW - Growth Hormone

KW - Humans

KW - Infant, Newborn

KW - Infant, Small for Gestational Age

KW - Male

KW - Practice Guidelines as Topic

KW - Randomized Controlled Trials as Topic

M3 - Tidsskriftartikel

C2 - 16513050

SN - 1399-4174

VL - 168

SP - 889

EP - 895

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 9

ER -

Væksthormonbehandling af korte børn født small for gestational age

Abstract

Emneord

Fingeraftryk

Citationsformater